Matricelf

Matricelf Long-term Debt

Long-Term Debt of Matricelf (MTLF.TA) as of Oct 23, 2026.

Long-term Debt

-ILS

Last updated:

Long-Term Debt of Matricelf is 2026 - ILS. Long-Term Debt of Matricelf was 2025 - ILS. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Matricelf Stock analysis

What does Matricelf do? Matricelf Ltd. is a biotechnology company that engages in research and development of a platform for autologous matrix and cell implants in the field of regenerative medicine and tissue engineering. The firm develops a platform for autologous 3D printing of neutral human matrix, cells, tissues and organs implants. The implants are manufactured using cellular components originated from the patients themselves, to reduce potential immune response. The firm focuses on the treatment of spinal cord injury (SCI), but is also involved in developing treatment for additional medical conditions, including: Myocardial Infarction (MI), Parkinson’s disease and Age-related Macular Degeneration (AMD). Matricelf Ltd is a spin-out company from Tel Aviv University. Matricelf is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Matricelf stock

On Eulerpool you can find the complete historical development of Long-Term Debt Matricelf since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Matricelf historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Matricelf

All Key Metrics — Matricelf